Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
about
ADHD drugs and serious cardiovascular events in children and young adultsToxicity of amphetamines: an updateADHD medications and risk of serious cardiovascular events in young and middle-aged adults.Advances in understanding and treating ADHDLong-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesPharmacoepidemiological safety studies in children: a systematic reviewStimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorderCardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsDo prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.European guidelines on managing adverse effects of medication for ADHD.Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks?Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications.Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.Abuse and dependence liability analysis of methylphenidate in the spontaneously hypertensive rat model of attention-deficit/hyperactivity disorder (ADHD): what have we learned?Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies.Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?Cardiac autonomic dysfunction and arterial stiffness among children and adolescents with attention deficit hyperactivity disorder treated with stimulants.Cardiovascular Safety of Concomitant Use of Atypical Antipsychotics and Long-Acting Stimulants in Children and Adolescents With ADHD.Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.Assessment of Cardiovascular Risks due to Methylphenidate in Six Months of Treatment in Children with Attention Deficit and Hyperactivity Disorder
P2860
Q22250876-32469C75-121D-4831-85AD-005D99EF0199Q22252794-E52728E9-6F12-4529-AFBE-48FDA84EA1E5Q22253017-7F966824-1A7E-4A38-9468-17A681C18C09Q24601949-FCE67CC4-CD3A-4078-8D9C-332A7D92E945Q26822392-5CCCFA78-C3B1-466B-BC8C-7014CD75F680Q28077862-AA9B55FA-E038-474C-857D-1F26A0C6AF3CQ33160890-6E0B3008-62CF-4847-B639-B180BC107CB6Q34063584-9F42D840-E2F8-4314-BC4A-9EE8C8CB1F3EQ34220004-95C92405-ED18-407E-918F-9653420BA022Q34280107-441154AC-BD60-4FF4-95E0-4D1FF5C79B08Q34448884-A818FC4F-E30C-46AF-82B7-30788CF5B3DAQ34461113-A7FE5AC3-8062-4254-9111-DBBDA767CBE0Q37893536-EFBC6027-3F98-4445-85F6-FAB2E592B88BQ38060572-5B8CDF84-8401-4CF6-9B37-C4946CD4C9CEQ38087534-987CB370-6F2E-474D-998C-D3FC26BFFBDFQ38126419-6D2FE38C-AFB0-40BC-93A5-6520E5D7A456Q38242438-37BEF796-BD19-46BA-BE0A-3AAEC9E4025FQ40207017-B657E7C5-B083-4CD4-85CF-BA259E389D39Q40400512-4EE40825-9656-461C-AB66-F04B1BCFA6E2Q50800347-C01352AB-273F-4041-80CA-7E361053710DQ58276674-534CE020-670B-4D1C-BCAC-367A7C356F03
P2860
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
@en
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
@nl
type
label
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
@en
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
@nl
prefLabel
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
@en
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
@nl
P2093
P2860
P356
P1433
P1476
Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
@en
P2093
Almut Gertrud Winterstein
Arwa Saidi
Jonathan Shuster
Tobias Gerhard
P2860
P304
P356
10.1542/PEDS.2008-3138
P407
P577
2009-07-01T00:00:00Z